A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)

被引：7
|
作者：
Kim, Kunhwa [1 ]
Kantarjian, Hagop [1 ]
Borthakur, Gautam [2 ]
Takahashi, Koichi [1 ]
Short, Nicholas J. [1 ]
DiNardo, Courtney D. [1 ]
Jabbour, Elias J. [1 ]
Chien, Kelly S. [1 ]
Daver, Naval [2 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Adewale, Lade [1 ]
Montalban-Bravo, Guillermo [1 ]
Wierda, William G. [1 ]
Verstovsek, Srdan [1 ]
Konopleva, Marina [1 ]
Ravandi, Farhad [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1275
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study
    Wierzbowska, Agnieszka
    Pluta, Agnieszka
    Stelmach, Piotr
    Brzozowski, Kamil
    Czemerska, Magdalena
    Sobas, Marta
    Rybka, Justyna
    Wrobel, Tomasz
    Zarzycka, Ewa
    Prejzner, Witold
    Zaucha, Jan M.
    Szczepaniak, Andrzej
    Gil, Lidia
    Giebel, Sebastian
    [J]. BLOOD, 2023, 142
  • [22] UCHMC 1812: A phase 1b trial of CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myeloid leukemia.
    Gaut, Daria Louise
    Callas, Bradley
    Damon, Lloyd Earl
    Jonas, Brian Andrew
    Jeyakumar, Deepa
    Borror, Catherine
    Osorio, Stephanie
    Ta, Teresa
    Park, Sunmin
    Schiller, Gary J.
    Wieduwilt, Matthew Joseph
    Oliai, Caspian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
    Villa, Kathleen F.
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur C.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (07) : 714 - 720
  • [24] Real-World Outcomes with CPX-351 Induction in Adults with Newly Diagnosed Acute Myeloid Leukemia
    Bennett, Joseph G.
    Gilmore, Drake
    Male, Heather J.
    Byrd, Kenneth P.
    Lin, Tara L.
    Gonzalez-Lugo, Jesus D.
    [J]. BLOOD, 2023, 142
  • [25] A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas K.
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
  • [26] A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 ( Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
    Keiffer, Gina
    Calabretta, Bruno
    Mazo, Alexander
    Outschoorn, Ubaldo Martinez
    Alpdogan, Onder
    Binder, Adam F.
    Porcu, Pierluigi
    Wilde, Lindsay
    Kasner, Margaret
    [J]. BLOOD, 2023, 142
  • [27] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Ghayas C. Issa
    Hagop M. Kantarjian
    Lianchun Xiao
    Jing Ning
    Yesid Alvarado
    Gautam Borthakur
    Naval Daver
    Courtney D. DiNardo
    Elias Jabbour
    Prithviraj Bose
    Nitin Jain
    Tapan M. Kadia
    Kiran Naqvi
    Naveen Pemmaraju
    Koichi Takahashi
    Srdan Verstovsek
    Micheal Andreeff
    Steven M. Kornblau
    Zeev Estrov
    Alessandra Ferrajoli
    Guillermo Garcia-Manero
    Maro Ohanian
    William G. Wierda
    Farhad Ravandi
    Jorge E. Cortes
    [J]. Leukemia, 2020, 34 : 2914 - 2924
  • [28] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Issa, Ghayas C.
    Kantarjian, Hagop M.
    Xiao, Lianchun
    Ning, Jing
    Alvarado, Yesid
    Borthakur, Gautam
    Daver, Naval
    DiNardo, Courtney D.
    Jabbour, Elias
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Naqvi, Kiran
    Pemmaraju, Naveen
    Takahashi, Koichi
    Verstovsek, Srdan
    Andreeff, Micheal
    Kornblau, Steven M.
    Estrov, Zeev
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Wierda, William G.
    Ravandi, Farhad
    Cortes, Jorge E.
    [J]. LEUKEMIA, 2020, 34 (11) : 2914 - 2924
  • [29] V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
    Agresta, Laura
    O'Brien, Maureen M.
    Mizuno, Kana
    Norris, Robin
    Breese, Erin H.
    Phillips, Christine L.
    Burns, Karen
    Mizukawa, Benjamin
    Lee, Lynn
    Lane, Adam
    Lorsbach, Robert B.
    Ryan, Thomas D.
    Desai, Pankaj B.
    Vinks, Alexander A.
    Grimes, H. Leighton
    Perentesis, John P.
    Absalon, Michael J.
    [J]. BLOOD, 2019, 134
  • [30] CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    Kovacsovics, Tibor
    Hogge, Donna E.
    Kolitz, Jonathan E.
    Tallman, Martin S.
    Hoering, Antje
    Chiarella, Michael T.
    Louie, Arthur C.
    Feldman, Eric
    [J]. BLOOD, 2012, 120 (21)
12345